CSPC Pharmaceutical Group Management
Management criteria checks 2/4
CSPC Pharmaceutical Group's CEO is Cuilong Zhang, appointed in May 2022, has a tenure of 2.5 years. total yearly compensation is CN¥13.47M, comprised of 5.1% salary and 94.9% bonuses, including company stock and options. directly owns 0.043% of the company’s shares, worth HK$25.65M. The average tenure of the management team and the board of directors is 2.5 years and 7.7 years respectively.
Key information
Cuilong Zhang
Chief executive officer
CN¥13.5m
Total compensation
| CEO salary percentage | 5.1% |
| CEO tenure | 2.5yrs |
| CEO ownership | 0.04% |
| Management average tenure | 2.5yrs |
| Board average tenure | 7.7yrs |
Recent management updates
Recent updates
Is CSPC Pharmaceutical Group Limited (HKG:1093) Trading At A 48% Discount?
Nov 15
Here's Why CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt Responsibly
Oct 16Earnings Not Telling The Story For CSPC Pharmaceutical Group Limited (HKG:1093) After Shares Rise 26%
Sep 30CSPC Pharmaceutical Group Limited (HKG:1093) Investors Are Less Pessimistic Than Expected
Aug 08Here's Why CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt Responsibly
Jun 17CSPC Pharmaceutical Group Limited Just Recorded A 20% Revenue Beat: Here's What Analysts Think
May 29CSPC Pharmaceutical Group (HKG:1093) Has Announced A Dividend Of CN¥0.14
May 21CSPC Pharmaceutical Group (HKG:1093) Will Pay A Dividend Of CN¥0.14
Apr 29There's Reason For Concern Over CSPC Pharmaceutical Group Limited's (HKG:1093) Price
Apr 22CSPC Pharmaceutical Group's (HKG:1093) Dividend Will Be CN¥0.14
Apr 01CSPC Pharmaceutical Group Limited (HKG:1093) Shares Could Be 49% Below Their Intrinsic Value Estimate
Jan 22Some Confidence Is Lacking In CSPC Pharmaceutical Group Limited's (HKG:1093) P/E
Jan 04Are Investors Undervaluing CSPC Pharmaceutical Group Limited (HKG:1093) By 36%?
Oct 22Is CSPC Pharmaceutical Group (HKG:1093) A Risky Investment?
Sep 21CSPC Pharmaceutical Group Limited's (HKG:1093) Intrinsic Value Is Potentially 62% Above Its Share Price
Jul 09Does CSPC Pharmaceutical Group (HKG:1093) Have A Healthy Balance Sheet?
Jun 20CSPC Pharmaceutical Group's (HKG:1093) Shareholders Will Receive A Bigger Dividend Than Last Year
Jun 01CSPC Pharmaceutical Group (HKG:1093) Is Increasing Its Dividend To CN¥0.11
Apr 04CSPC Pharmaceutical Group Limited's (HKG:1093) Intrinsic Value Is Potentially 92% Above Its Share Price
Mar 12CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | CN¥5b |
| Jun 30 2024 | n/a | n/a | CN¥6b |
| Mar 31 2024 | n/a | n/a | CN¥6b |
| Dec 31 2023 | CN¥13m | CN¥693k | CN¥6b |
| Sep 30 2023 | n/a | n/a | CN¥6b |
| Jun 30 2023 | n/a | n/a | CN¥6b |
| Mar 31 2023 | n/a | n/a | CN¥6b |
| Dec 31 2022 | CN¥11m | CN¥693k | CN¥6b |
| Sep 30 2022 | n/a | n/a | CN¥6b |
| Jun 30 2022 | n/a | n/a | CN¥6b |
| Mar 31 2022 | n/a | n/a | CN¥6b |
| Dec 31 2021 | CN¥9m | CN¥693k | CN¥6b |
| Sep 30 2021 | n/a | n/a | CN¥6b |
| Jun 30 2021 | n/a | n/a | CN¥6b |
| Mar 31 2021 | n/a | n/a | CN¥5b |
| Dec 31 2020 | CN¥9m | CN¥693k | CN¥5b |
| Sep 30 2020 | n/a | n/a | CN¥4b |
| Jun 30 2020 | n/a | n/a | CN¥4b |
| Mar 31 2020 | n/a | n/a | CN¥4b |
| Dec 31 2019 | CN¥7m | CN¥693k | CN¥4b |
| Sep 30 2019 | n/a | n/a | CN¥4b |
| Jun 30 2019 | n/a | n/a | CN¥3b |
| Mar 31 2019 | n/a | n/a | CN¥3b |
| Dec 31 2018 | CN¥4m | CN¥298k | CN¥3b |
Compensation vs Market: Cuilong's total compensation ($USD1.86M) is above average for companies of similar size in the Hong Kong market ($USD735.87K).
Compensation vs Earnings: Cuilong's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
CEO
Cuilong Zhang (55 yo)
2.5yrs
Tenure
CN¥13,472,000
Compensation
Mr. Cuilong Zhang has been the Vice Chairman of CSPC Pharmaceutical Group Ltd since May 21, 2019 and serves as its Chief Executive Officer since May 27, 2022. He was Rotating Chief Executive Officer of CSP...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 27.6yrs | CN¥26.68m | 24.16% HK$ 14.4b | |
| Vice-Chairman & CEO | 2.5yrs | CN¥13.47m | 0.043% HK$ 25.6m | |
| Executive Director & Chief Scientist | 6.9yrs | CN¥9.42m | 0.039% HK$ 23.1m | |
| Executive Director | no data | CN¥4.92m | 0.013% HK$ 7.7m | |
| Executive Director | no data | CN¥5.74m | 0.013% HK$ 7.7m | |
| Executive Director | no data | CN¥4.90m | 0.013% HK$ 7.7m | |
| Executive Director | no data | CN¥4.02m | 0.026% HK$ 15.4m | |
| Group Executive President | no data | no data | no data | |
| Executive Director | less than a year | no data | no data | |
| Executive president & President of Global Research and Development | less than a year | no data | no data | |
| Company Secretary | 3.8yrs | no data | no data |
2.5yrs
Average Tenure
54.5yo
Average Age
Experienced Management: 1093's management team is considered experienced (2.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 27.6yrs | CN¥26.68m | 24.16% HK$ 14.4b | |
| Vice-Chairman & CEO | 6.3yrs | CN¥13.47m | 0.043% HK$ 25.6m | |
| Executive Director & Chief Scientist | 6.9yrs | CN¥9.42m | 0.039% HK$ 23.1m | |
| Executive Director | 18.1yrs | CN¥4.92m | 0.013% HK$ 7.7m | |
| Executive Director | 14.1yrs | CN¥5.74m | 0.013% HK$ 7.7m | |
| Executive Director | 12.8yrs | CN¥4.90m | 0.013% HK$ 7.7m | |
| Executive Director | 4yrs | CN¥4.02m | 0.026% HK$ 15.4m | |
| Group Executive President | less than a year | no data | no data | |
| Executive Director | less than a year | no data | no data | |
| Independent Non-Executive Director | 3.8yrs | CN¥340.00k | no data | |
| Independent Non-Executive Director | 11.9yrs | CN¥142.00k | no data | |
| Independent Non-Executive Director | 8.4yrs | CN¥142.00k | no data |
7.7yrs
Average Tenure
54.5yo
Average Age
Experienced Board: 1093's board of directors are considered experienced (7.7 years average tenure).